<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">MD-Onco</journal-id><journal-title-group><journal-title xml:lang="en">MD-Onco</journal-title><trans-title-group xml:lang="ru"><trans-title>MD-Onco</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2782-3202</issn><issn publication-format="electronic">2782-6171</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">200</article-id><article-id pub-id-type="doi">10.17650/2782-3202-2025-5-3-80-88</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>RARE COMPLICATIONS, QUALITY OF LIFE, AND FOLLOW-UP CARE OF ONCOHEMATOLOGICAL PATIENTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>РЕДКИЕ ОСЛОЖНЕНИЯ, КАЧЕСТВО ЖИЗНИ И ДИСПАНСЕРНОЕ НАБЛЮДЕНИЕ ОНКОГЕМАТОЛОГИЧЕСКИХ БОЛЬНЫХ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">The impact of chemotherapy on pituitary hormonal function in pubertal children with Hodgkin’s lymphoma</article-title><trans-title-group xml:lang="ru"><trans-title>Влияние химиотерапевтического лечения на гормональную функцию гипофиза у детей пубертатного возраста с лимфомой Ходжкина</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7334-3034</contrib-id><name-alternatives><name xml:lang="en"><surname>Dzhavadov</surname><given-names>D. A.</given-names></name><name xml:lang="ru"><surname>Джавадов</surname><given-names>Д. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14th Line St., Rostov-on-Don 344037</p><p>29 Nakhichevansky Ave., Rostov-on-Don 344022</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14-я линия, 63</p><p>344022 Ростов-на-Дону, пр-кт Нахичеванский, 29</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3618-6890</contrib-id><name-alternatives><name xml:lang="en"><surname>Frantsiyants</surname><given-names>E. M.</given-names></name><name xml:lang="ru"><surname>Франциянц</surname><given-names>Е. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14th Line St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14-я линия, 63</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2302-8271</contrib-id><name-alternatives><name xml:lang="en"><surname>Bandovkina</surname><given-names>V. A.</given-names></name><name xml:lang="ru"><surname>Бандовкина</surname><given-names>В. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14th Line St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14-я линия, 63</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6681-3253</contrib-id><name-alternatives><name xml:lang="en"><surname>Kozel</surname><given-names>Yu. Yu.</given-names></name><name xml:lang="ru"><surname>Козель</surname><given-names>Ю. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14th Line St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14-я линия, 63</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2124-3218</contrib-id><name-alternatives><name xml:lang="en"><surname>Dmitrieva</surname><given-names>V. V.</given-names></name><name xml:lang="ru"><surname>Дмитриева</surname><given-names>В. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14th Line St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14-я линия, 63</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0676-7398</contrib-id><name-alternatives><name xml:lang="en"><surname>Kozyuk</surname><given-names>O. V.</given-names></name><name xml:lang="ru"><surname>Козюк</surname><given-names>О. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14th Line St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14-я линия, 63</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2565-1518</contrib-id><name-alternatives><name xml:lang="en"><surname>Dimitriadi</surname><given-names>S. N.</given-names></name><name xml:lang="ru"><surname>Димитриади</surname><given-names>С. Н.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14th Line St., Rostov-on-Don 344037</p><p>29 Nakhichevansky Ave., Rostov-on-Don 344022</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14-я линия, 63</p><p>344022 Ростов-на-Дону, пр-кт Нахичеванский, 29</p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5202-7681</contrib-id><name-alternatives><name xml:lang="en"><surname>Mkrtchyan</surname><given-names>G. A.</given-names></name><name xml:lang="ru"><surname>Мкртчян</surname><given-names>Г. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>63 14th Line St., Rostov-on-Don 344037</p></bio><bio xml:lang="ru"><p>344037 Ростов-на-Дону, ул. 14-я линия, 63</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3635-8579</contrib-id><name-alternatives><name xml:lang="en"><surname>Aslanyan</surname><given-names>K. S.</given-names></name><name xml:lang="ru"><surname>Асланян</surname><given-names>К. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>14 339th Strelkovoy Divizii St., Rostov-on-Don 344015</p></bio><bio xml:lang="ru"><p>344015 Ростов-на-Дону, ул. 339-й Стрелковой Дивизии, 14</p></bio><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">National Medical Research Centre for Oncology, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр онкологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Rostov State Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Ростовский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Regional Children’s Clinical Hospital</institution></aff><aff><institution xml:lang="ru">ГБУ РО «Областная детская клиническая больница»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2025-09-21" publication-format="electronic"><day>21</day><month>09</month><year>2025</year></pub-date><volume>5</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>80</fpage><lpage>88</lpage><history><date date-type="received" iso-8601-date="2025-09-21"><day>21</day><month>09</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, ABV-Press</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, АБВ-пресс</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">ABV-Press</copyright-holder><copyright-holder xml:lang="ru">АБВ-пресс</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://mdonco.abvpress.ru/jour/about/editorialPolicies</ali:license_ref></license></permissions><self-uri xlink:href="https://mdonco.abvpress.ru/jour/article/view/200">https://mdonco.abvpress.ru/jour/article/view/200</self-uri><abstract xml:lang="en"><p>Background. Endocrine disorders are a significant long-term complication in children who have undergone anti-cancer treatment. Despite the relevance of this issue, the effects of chemotherapy (CT) on pituitary hormonal function in pubertal children with Hodgkin’s lymphoma (HL) remain poorly understood.Aim. To evaluate the levels of pituitary hormones (somatotropic (growth) hormone (GH), thyroid-stimulating (TSH), adrenocorticotropic (ACTH), luteinizing (LH), follicle-stimulating (FSH) hormones, prolactin) in pubertal children with HL before and after chemotherapy. Materials and methods. The study included 40 pubertal children (11–17 years old, median 13.65 years) diagnosed with HL (20 (50 %) boys and 20 (50 %) girls) – main group. The control group comprised 40 conditionally healthy children of the same age range (median age 15.25 years) with equal gender distribution. Blood samples from the HL group were collected before chemotherapy and after its completion (prior to radiotherapy). Hormone levels (GH, TSH, ACTH, LH, FSH, prolactin) were measured using standard radioimmunoassay and enzyme-linked immunosorbent assay kits. Reference values were based on hormone levels in the control group. Statistical analysis was performed using Statistica 10.Results. In girls with HL, pre-treatment levels of LH, FSH, and the LH/FSH ratio were elevated by 1.8-, 1.4-, and 1.3-fold, respectively, compared to the norm (p &lt;0.05). GH and ACTH levels were 1.6and 3.1-fold below normal, respectively (p &lt;0.05). After CT, LH levels decreased by 2.8-fold from baseline and by 1.5-fold relative to the norm, while FSH levels remained elevated at 1.6-fold above the norm (p &lt;0.05). The LH/FSH ratio dropped by 2.6-fold relative to the norm and by 3.2-fold compared to baseline. Prolactin levels post-CT were 1.7-fold above the norm and 1.5-fold above baseline (p &lt;0.05). GH levels were 7.8-fold lower than normal and 4.8-fold below baseline, whereas ACTH levels increased by 6.7-fold over baseline and were twice the normal level.In boys with HL, pre-treatment LH levels and LH/FSH ratio were 1.5and 1.4-fold below normal, respectively (p &lt;0.05). Prolactin was 1.8-fold higher than normal (p &lt;0.05), and GH was 3.6-fold below normal. After CT, LH increased by 1.4-fold compared to baseline, reaching reference values (p &lt;0.05).Based on FSH levels, patients were divided into two subgroups: in 50 %, FSH remained within the normal range, while in the other 50 %, it increased ten-fold. The LH/FSH ratio remained normal in the first subgroup but was 11-fold below normal and 7.8-fold below baseline in the second. Post-treatment prolactin levels were 3.6-fold above normal and twice the baseline level. GH increased threefold from baseline and normalized. ACTH exceeded both normal and baseline levels two-fold. TSH levels decreased by 1.8-fold compared to both the norm and baseline (p &lt;0.05).Conclusion. The development of HL in pubertal children is associated with suppression of adenohypophyseal function and an imbalance in the synthesis of tropic hormones. Antitumor therapy does not generally restore normal hormone levels, which may be due to dysregulation of the central endocrine axes or the presence of extrapituitary sources of hormone production.</p></abstract><trans-abstract xml:lang="ru"><p>Введение. Эндокринные нарушения у детей, перенесших онкологические заболевания, представляют собой значимые отдаленные последствия противоопухолевой терапии. Несмотря на актуальность проблемы, степень изученности влияния химиотерапии (ХТ) на гормональную функцию гипофиза у детей пубертатного возраста с лимфомой Ходжкина (ЛХ) остается недостаточной.Цель исследования – изучить уровни гипофизарных гормонов (соматотропного (СТГ), тиреотропного (ТТГ), адренокортикотропного (АКТГ), лютеинизирующего (ЛГ), фолликулостимулирующего (ФСГ) гормонов, пролактина) в крови у детей пубертатного возраста с ЛХ до начала ХТ и после ее окончания.Материалы и методы. В исследование были включены дети (n = 40) пубертатного возраста (от 11 до 17 лет, медиана 13,65 года), обоих полов (20 (50 %) мальчиков и 20 (50 %) девочек) с ЛХ (основная группа). Контрольную группу составили условно здоровые дети (n = 40) в возрасте от 11 до 17 лет (медиана 15,25 года) в равном половом соотношении. В образцах крови у детей основной группы до начала и после завершения курсов ХТ (до проведения лучевой терапии) с использованием стандартных наборов, применяемых в радиоиммунном и иммуноферментном анализе, определяли уровни гормонов гипофиза (СТГ, ТТГ, АКТГ, ЛГ, ФСГ, пролактин). В качестве нормы использовали средние уровни гормонов гипофиза, полученные из образцов крови условно здоровых детей (n = 40) пубертатного возраста. Статистическую обработку результатов проводили с помощью программы Statistica 10.Результаты. До лечения уровни ЛГ, ФСГ и соотношение ЛГ/ФСГ у девочек с ЛХ были выше нормы в 1,8; 1,4 и 1,3 раза соответственно (p &lt;0,05). Значения СТГ и АКТГ находились ниже нормы в 1,6 и 3,1 раза соответственно (p &lt;0,05). После завершения курсов ХТ было зафиксировано снижение уровня ЛГ в 2,8 раза по сравнению с исходным и в 1,5 раза относительно нормы на фоне повышенного уровня ФСГ, который превышал норму в 1,6 раза (p &lt;0,05). Показатель соотношения ЛГ/ФСГ снизился в 2,6 раза относительно нормы и в 3,2 раза по сравнению с исходным значением. Концентрация пролактина после ХТ превышала норму в 1,7 раза и исходный уровень – в 1,5 раза (p &lt;0,05). Уровень СТГ снизился в 7,8 раза по сравнению с нормой и был в 4,8 раза ниже исходного значения. В то же время уровень АКТГ увеличился в 6,7 раза по сравнению с исходным значением и в 2 раза превышал норму.У мальчиков с ЛХ до лечения уровень ЛГ и соотношение ЛГ/ФСГ были ниже нормы в 1,5 и 1,4 раза соответственно (p &lt;0,05). Концентрация пролактина была выше нормы в 1,8 раза (p &lt;0,05). Уровень СТГ был ниже нормы в 3,6 раза. После завершения курсов ХТ зафиксировано увеличение уровня ЛГ в 1,4 раза по сравнению с исходным уровнем, что соответствовало референсным значениям (p &lt;0,05).В зависимости от уровня ФСГ в крови пациентов разделили на 2 подгруппы: у 50 % детей показатель достигал нормы, тогда как у остальных наблюдалось резкое увеличение уровня ФСГ – в 10 раз выше нормы. Соотношение ЛГ/ФСГ у детей 1-й подгруппы оставалось в пределах нормы, а у детей 2-й подгруппы – ниже в 11 раз по сравнению с нормой и в 7,8 раза относительно исходного уровня. После лечения концентрация пролактина превышала нормальные значения в 3,6 раза и исходный уровень в 2 раза. Уровень СТГ увеличился в 3 раза по сравнению с исходным и достиг нормы. Концентрация АКТГ превышала норму и исходный уровень в 2 раза. Значение ТТГ снизилось по сравнению с нормой и исходным уровнем в 1,8 раза (p &lt;0,05). Заключение. Развитие ЛХ у детей пубертатного возраста сопровождается угнетением работы одного из основных центральных регуляторных звеньев – аденогипофиза – и нарушением баланса синтеза его клетками тропных гормонов. Противоопухолевое лечение в большинстве случаев не оказывает нормализующего воздействия на уровень тропных гормонов, что может быть связано как с ответом основных регуляторных эндокринных осей, так и с наличием в крови тропных гормонов, синтезирующихся экстрагипофизарно. </p></trans-abstract><kwd-group xml:lang="en"><kwd>Hodgkin’s lymphoma</kwd><kwd>adolescents</kwd><kwd>hormones</kwd><kwd>pituitary gland</kwd><kwd>growth hormone</kwd><kwd>thyroid-stimulating hormone</kwd><kwd>luteinizing hormone</kwd><kwd>follicle-stimulating hormone</kwd><kwd>prolactin</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>лимфома Ходжкина</kwd><kwd>подростки</kwd><kwd>гормоны</kwd><kwd>гипофиз</kwd><kwd>соматотропин</kwd><kwd>тиреотропный гормон</kwd><kwd>лютеинизирующий гормон</kwd><kwd>фолликулостимулирующий гормон</kwd><kwd>пролактин</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Arega G., Adam H., Girma A. et al. Pediatric T-cell/histiocyte-rich large B-cell lymphoma (THRLBC) in an 8-year-old male child: a case report. Case Rep Oncol Med 2025;2025:8869045. DOI: 10.1155/crom/8869045</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>National Cancer Institute: NCCR. An interactive website for NCCR cancer statistics. Bethesda, MD: National Cancer Institute. Available at: https://nccrexplorer.ccdi.cancer.gov (Date of access: 05.01.2025).</mixed-citation></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Malignant neoplasms in Russia in 2016 (incidence and mortality). Ed. by A.D. Kaprin, V.V. Starinskiy, G.V. Petrova, Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2018. 38 p. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Злокачественные новообразования в России в 2016 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2018. 38 с.</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><mixed-citation>Che Y., Ding X., Xu L. et al. Advances in the treatment of Hodgkinʼs lymphoma (Review). Int J Oncol 2023;62(5):61. DOI: 10.3892/ijo.2023.5509</mixed-citation></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Valiev T.T., Morozova O.V., Kovrigina A.M. et al. Diagnosis and treatment of anaplastic large-cell lymphomas in children.</mixed-citation><mixed-citation xml:lang="ru">Валиев Т.Т., Морозова О.В., Ковригина А.М. и др. Диагностика и лечение анапластических крупноклеточных лимфом у детей. Гематология и трансфузиология 2012;57(1):3–9.</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><mixed-citation>Gematologiya i transfuziologiya = Russian Journal of Hematology and Transfusiology 2012;57(1):3–9. (In Russ.).</mixed-citation></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Gurieva O.D., Valiev T.T., Pavlovskaya A.I. Histiocytic neoplasms: modern aspects of pathogenesis, classification, diagnosis and treatment. Onkogematologiya = Oncohematology 2022;17(1):10–25. (In Russ.). DOI: 10.17650/1818-8346-2022-17-1-10-25</mixed-citation><mixed-citation xml:lang="ru">Гурьева О.Д., Валиев Т.Т., Павловская А.И. Гистиоцитарные опухоли: современные аспекты патогенеза, классификации, диагностики и лечения. Онкогематология 2022;17(1):10–25. DOI: 10.17650/1818-8346-2022-17-1-10-25</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Kulichkina N.S., Belyaeva E.S., Popa A.V. et al. The predictive role of interim pet-ct in the treatment of Hodgkinʼs lymphoma in children. Sovremennaya onkologiya = Journal of Modern Oncology 2017;19(3):52–6. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Куличкина Н.С., Беляева Е.С., Попа А.В. и др. Роль промежуточной позитронно-эмиссионной томографии, совмещенной с компьютерной томографией, в тактике лечения лимфомы Ходжкина у детей. Современная онкология 2017;19(3):52–6.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Tsaplina N.S., Kozlov A.V., Valiev T.T. et al. Treatment of children with relapsed and refractory classical Hodgkinʼs lymphoma: the experience of two centers. Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2024;11(3):22–9. (In Russ.). DOI: 10.21682/2311-1267-2024-11-3-22-29</mixed-citation><mixed-citation xml:lang="ru">Цаплина Н.С., Козлов А.В., Валиев Т.Т. и др. Лечение детей с рецидивами и рефрактерными формами классической лимфомы Ходжкина: опыт двух центров. Российский журнал детской гематологии и онкологии 2024;11(3):22–9. DOI: 10.21682/2311-1267-2024-11-3-22-29</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Gurieva O.D., Savelyeva M.I., Valiev T.T. Genetic basis of clinical variants of chemotherapy toxicity in children with acute lymphoblastic leukemia (literature review). Rossiyskiy zhurnal detskoy gematologii i onkologii = Russian Journal of Pediatric Hematology and Oncology 2021;8(4):60–70. (In Russ.). DOI: 10.21682/2311-1267-2021-8-4-60-70</mixed-citation><mixed-citation xml:lang="ru">Гурьева О.Д., Савельева М.И., Валиев Т.Т. Генетические основы клинических вариантов токсичности химиотерапии у детей с острым лимфобластным лейкозом (обзор литературы). Российский журнал детской гематологии и онкологии 2021;8(4):60–70. DOI: 10.21682/2311-1267-2021-8-4-60-70</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><mixed-citation>Casano-Sancho P., Izurieta-Pacheco A.C. Endocrine late effects in childhood cancer survivors. Cancers (Basel) 2022;14(11):2630. DOI: 10.3390/cancers14112630</mixed-citation></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Zaeva G.E., Valiev T.T., Gavrilenko T.F. et al. Long-term effects of pediatric cancer therapy: 35-year clinical experience. Sovremennaya onkologiya = Journal of Modern Oncology 2015;18(1):55–60. (In Russ.).</mixed-citation><mixed-citation xml:lang="ru">Заева Г.Е., Валиев Т.Т., Гавриленко Т.Ф. и др. Отдаленные последствия терапии злокачественных опухолей у детей: 35-летний опыт клинических наблюдений. Современная онкология 2016;18(1):55–60.</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Pavlova T.Yu., Valiev T.T. Second malignant tumors in pediatric cancer survivors. Pediatriya. Consilium Medicum = Pediatrics. Consilium Medicum 2020;2:12–6. (In Russ.). DOI: 10.26442/26586630.2020.2.200234</mixed-citation><mixed-citation xml:lang="ru">Sovremennaya onkologiya = Journal of Modern Oncology 2015;18(1):55–60. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Chemaitilly W., Li Z., Brinkman T.M. et al. Primary hypothyroidism in childhood cancer survivors: prevalence, risk factors, and long-term consequences. Cancer 2022;128(3):606–14. DOI: 10.1002/cncr.33969</mixed-citation><mixed-citation xml:lang="ru">Павлова Т.Ю., Валиев Т.Т. Вторые злокачественные опухоли у лиц, перенесших онкологическое заболевание в детстве. Педиатрия. Consilium Medicum 2020;2:12–6. DOI: 10.26442/26586630.2020.2.200234</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Sklar C.A., Antal Z., Chemaitilly W. et al. Hypothalamic-pituitary and growth disorders in survivors of childhood cancer: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2018;103(8):2761–84. DOI: 10.1210/jc.2018-01175</mixed-citation><mixed-citation xml:lang="ru">Pavlova T.Yu., Valiev T.T. Second malignant tumors in pediatric cancer survivors. Pediatriya. Consilium Medicum = Pediatrics. Consilium Medicum 2020;2:12–6. (In Russ.). DOI: 10.26442/26586630.2020.2.200234</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Friedman D.N., Tonorezos E.S., Cohen P. Diabetes and metabolic syndrome in survivors of childhood cancer. Horm Res Paediatr 2019;91(2):118–27. DOI: 10.1159/000495698</mixed-citation><mixed-citation xml:lang="ru">Chemaitilly W., Li Z., Brinkman T.M. et al. Primary hypothyroidism in childhood cancer survivors: prevalence, risk factors, and long-term consequences. Cancer 2022;128(3):606–14. DOI: 10.1002/cncr.33969</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Pollock N.I., Cohen L.E. Growth hormone deficiency and treatment in childhood cancer survivors. Front Endocrinol (Lausanne) 2021;12:745932. DOI: 10.3389/fendo.2021.745932</mixed-citation><mixed-citation xml:lang="ru">Sklar C.A., Antal Z., Chemaitilly W. et al. Hypothalamic-pituitary and growth disorders in survivors of childhood cancer: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2018;103(8):2761–84. DOI: 10.1210/jc.2018-01175</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">National Institute for Health and Care Excellence (NICE). NICE Clinical Guidelines, No. 243. Adrenal insufficiency: identification and management. 2024.</mixed-citation><mixed-citation xml:lang="ru">Friedman D.N., Tonorezos E.S., Cohen P. Diabetes and metabolic syndrome in survivors of childhood cancer. Horm Res Paediatr 2019;91(2):118–27. DOI: 10.1159/000495698</mixed-citation></citation-alternatives></ref><ref id="B19"><label>19.</label><citation-alternatives><mixed-citation xml:lang="en">Wei C., Crowne E.C. The hypothalamic-pituitary-adrenal axis in childhood cancer survivors. Endocr Relat Cancer 2018;25(10):R479–R96. DOI: 10.1530/ERC-18-0217</mixed-citation><mixed-citation xml:lang="ru">Pollock N.I., Cohen L.E. Growth hormone deficiency and treatment in childhood cancer survivors. Front Endocrinol (Lausanne) 2021;12:745932. DOI: 10.3389/fendo.2021.745932</mixed-citation></citation-alternatives></ref><ref id="B20"><label>20.</label><citation-alternatives><mixed-citation xml:lang="en">Lewis A., Thant A.A., Aslam A. et al. Diagnosis and management of adrenal insufficiency. Clin Med (Lond) 2024;23(2):115–8. DOI: 10.7861/clinmed.2023-0067</mixed-citation><mixed-citation xml:lang="ru">National Institute for Health and Care Excellence (NICE). NICE Clinical Guidelines, No. 243. Adrenal insufficiency: identification and management. 2024.</mixed-citation></citation-alternatives></ref><ref id="B21"><label>21.</label><citation-alternatives><mixed-citation xml:lang="en">Bandovkina V.A., Frantsiyants E.M., Salatova A.M. et al. Thyroid status in patients with early stages of cancer of various localization. Issledovaniya i praktika v meditsine = Researchʼn Practical Medicine Journal 2024;11(2):46–56. (In Russ.). DOI: 10.17709/2410-1893-2024-11-2-4</mixed-citation><mixed-citation xml:lang="ru">Wei C., Crowne E.C. The hypothalamic-pituitary-adrenal axis in childhood cancer survivors. Endocr Relat Cancer 2018;25(10):R479–R96. DOI: 10.1530/ERC-18-0217</mixed-citation></citation-alternatives></ref><ref id="B22"><label>22.</label><citation-alternatives><mixed-citation xml:lang="en">Kit O.I., Frantsiyants E.M., Bandovkina V.A. et al. The content of steroid hormones, their precursors and ACTH in the blood of patients with pathology of pancreas. Onkologiya. Zhurnal im. P.A. Hertzena = P.A. Herzen Journal of Oncology 2020;9(3):29–33. (In Russ.). DOI: 10.17116/onkolog202090312</mixed-citation><mixed-citation xml:lang="ru">Lewis A., Thant A.A., Aslam A. et al. Diagnosis and management of adrenal insufficiency. Clin Med (Lond) 2024;23(2):115–8. DOI: 10.7861/clinmed.2023-0067</mixed-citation></citation-alternatives></ref><ref id="B23"><label>23.</label><citation-alternatives><mixed-citation xml:lang="en">Bandovkina V.A., Frantsiyants E.M., Cheryarina N.D. et al. The response to chemotherapy in patients with breast cancer may depend not only on the biological subtype of the tumor, but also on the hormonal status of the patient. Sovremenniye problemy nauky i obrazivaniya = Modern problems of science and education 2020;5. (In Russ.). DOI: 10.17513/spno.30177</mixed-citation><mixed-citation xml:lang="ru">Бандовкина В.А., Франциянц Е.М., Салатова А.М. и др. Тиреоидный статус у пациентов на ранних стадиях рака различной локализации. Researchʼn Practical Medicine Journal (Исследования и практика в медицине) 2024;11(2):46–56. DOI: 10.17709/2410-1893-2024-11-2-4</mixed-citation></citation-alternatives></ref><ref id="B24"><label>24.</label><citation-alternatives><mixed-citation xml:lang="en">Manosroi W., Chirayucharoensak J., Chai-Adisaksopha C., Phinyo P. Hormonal changes after R-CHOP chemotherapy in patients with diffuse large B-cell lymphoma: a prospective study. Medicina (Kaunas) 2022;58(6):710. DOI: 10.3390/medicina58060710</mixed-citation><mixed-citation xml:lang="ru">Кит О.И., Франциянц Е.М., Бандовкина В.А. и др. Содержание стероидных гормонов, их предшественников и АКТГ в крови больных с патологией поджелудочной железы. Онкология. Журнал им. П.А. Герцена 2020;9(3):29–33. DOI: 10.17116/onkolog2020903129</mixed-citation></citation-alternatives></ref><ref id="B25"><label>25.</label><citation-alternatives><mixed-citation xml:lang="en">Lebbink C.A., van den Bos C., Dierselhuis M.P. et al. Thyroid Profile in the First Three Months after Starting Treatment in Children with Newly Diagnosed Cancer. Cancers (Basel). 2023 Feb 27;15(5):1500. DOI: 10.3390/cancers15051500.</mixed-citation><mixed-citation xml:lang="ru">Бандовкина В.А., Франциянц Е.М., Черярина Н.Д. и др. Ответ на химиотерапию у больных раком молочной железы может зависеть не только от биологического подтипа опухоли, но и от гормонального статуса пациентки. Современные проблемы науки и образования 2020;5. DOI: 10.17513/spno.30177</mixed-citation></citation-alternatives></ref><ref id="B26"><label>26.</label><citation-alternatives><mixed-citation xml:lang="en">Thabit J.A., Almzaiel A.J., Kadhim M.I., Alrufaie M.A. The impact of reproductive hormone changes on the immune response of patients with leukemia. Anaesth Pain Intensive Care 2023;27(5):585−91. DOI: 10.35975/apic.v27i5.2317</mixed-citation><mixed-citation xml:lang="ru">Manosroi W., Chirayucharoensak J., Chai-Adisaksopha C., Phinyo P. Hormonal changes after R-CHOP chemotherapy in patients with diffuse large B-cell lymphoma: a prospective study. Medicina (Kaunas) 2022;58(6):710. DOI: 10.3390/medicina58060710</mixed-citation></citation-alternatives></ref><ref id="B27"><label>27.</label><citation-alternatives><mixed-citation xml:lang="en">Frantsiyants E. M., Bandovkina V. A., Dzhavadov D. A. et al. Thyroid status in adolescent patients with Hodgkin’s lymphoma before and after antitumor treatment. Sovremenniye problemy nauky i obrazivaniya = Modern problems of science and education. 2024;5. (In Russ.). DOI: 10.17513/spno.33598</mixed-citation><mixed-citation xml:lang="ru">Lebbink C.A., van den Bos C., Dierselhuis M.P. et al. Thyroid Profile in the First Three Months after Starting Treatment in Children with Newly Diagnosed Cancer. Cancers (Basel). 2023 Feb 27;15(5):1500. DOI: 10.3390/cancers15051500.</mixed-citation></citation-alternatives></ref><ref id="B28"><label>28.</label><citation-alternatives><mixed-citation xml:lang="en">Drechsel K.C.E., Broer S.L., van Breda H.M.K. et al. Semen analysis and reproductive hormones in boys with classical Hodgkin lymphoma treated according to the EuroNet-PHL-C2 protocol. Hum Reprod 2024;39(11):2411–22. DOI: 10.1093/humrep/deae204</mixed-citation><mixed-citation xml:lang="ru">Thabit J.A., Almzaiel A.J., Kadhim M.I., Alrufaie M.A. The impact of reproductive hormone changes on the immune response of patients with leukemia. Anaesth Pain Intensive Care 2023;27(5):585−91. DOI: 10.35975/apic.v27i5.2317</mixed-citation></citation-alternatives></ref><ref id="B29"><label>29.</label><citation-alternatives><mixed-citation xml:lang="en">Crowne E., Gleeson H., Benghiat H. et al. Effect of cancer treatment on hypothalamic-pituitary function. Lancet Diabetes Endocrinol 2015;3(7):568–76. DOI: 10.1016/S2213-8587(15)00008-X</mixed-citation><mixed-citation xml:lang="ru">Франциянц Е.М., Бандовкина В.А., Джавадов Д.А. и др. Тиреоидный статус у подростков, больных лимфомой Ходжкина, до и после противоопухолевого лечения. Современные проблемы науки и образования. 2024;5. DOI: 10.17513/spno.33598</mixed-citation></citation-alternatives></ref><ref id="B30"><label>30.</label><citation-alternatives><mixed-citation xml:lang="en">Link-Rachner C.S., Gobel A., Jaschke N.P., Rachner T.D. Endocrine health in survivors of adult-onset cancer. Lancet Diabetes Endocrinol 2024;12(5):350–64. DOI: 10.1016/S2213-8587(24)00088-3</mixed-citation><mixed-citation xml:lang="ru">Drechsel K.C.E., Broer S.L., van Breda H.M.K. et al. Semen analysis and reproductive hormones in boys with classical Hodgkin lymphoma treated according to the EuroNet-PHL-C2 protocol. Hum Reprod 2024;39(11):2411–22. DOI: 10.1093/humrep/deae204</mixed-citation></citation-alternatives></ref><ref id="B31"><label>31.</label><citation-alternatives><mixed-citation xml:lang="en">Werner H., Laron Z. Role of the GH-IGF1 system in progression of cancer. Mol Cell Endocrinol 2020;518:111003. DOI: 10.1016/j.mce.2020.111003</mixed-citation><mixed-citation xml:lang="ru">Crowne E., Gleeson H., Benghiat H. et al. Effect of cancer treatment on hypothalamic-pituitary function. Lancet Diabetes Endocrinol 2015;3(7):568–76. DOI: 10.1016/S2213-8587(15)00008-X</mixed-citation></citation-alternatives></ref><ref id="B32"><label>32.</label><citation-alternatives><mixed-citation xml:lang="en">Boguszewski M.C.S., Boguszewski C.L., Chemaitilly W. et al. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. Eur J Endocrinol 2022;186(6):P35–P52. DOI: 10.1530/EJE-21-1186</mixed-citation><mixed-citation xml:lang="ru">Link-Rachner C.S., Gobel A., Jaschke N.P., Rachner T.D. Endocrine health in survivors of adult-onset cancer. Lancet Diabetes Endocrinol 2024;12(5):350–64. DOI: 10.1016/S2213-8587(24)00088-3</mixed-citation></citation-alternatives></ref><ref id="B33"><label>33.</label><citation-alternatives><mixed-citation xml:lang="en">Kazmi S.R.H., Can A.S. Luteinizing hormone deficiency. Treasure Island (FL): StatPearls Publishing, 2024.</mixed-citation><mixed-citation xml:lang="ru">Werner H., Laron Z. Role of the GH-IGF1 system in progression of cancer. Mol Cell Endocrinol 2020;518:111003. DOI: 10.1016/j.mce.2020.111003</mixed-citation></citation-alternatives></ref><ref id="B34"><label>34.</label><citation-alternatives><mixed-citation xml:lang="en">Hsueh A.J., He J. Gonadotropins and their receptors: coevolution, genetic variants, receptor imaging, and functional antagonists. Biol Reprod 2018;99(1):3–12. DOI: 10.1093/biolre/ioy012</mixed-citation><mixed-citation xml:lang="ru">Boguszewski M.C.S., Boguszewski C.L., Chemaitilly W. et al. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. Eur J Endocrinol 2022;186(6):P35–P52. DOI: 10.1530/EJE-21-1186</mixed-citation></citation-alternatives></ref><ref id="B35"><label>35.</label><citation-alternatives><mixed-citation xml:lang="en">Chu Y.L., Xu Y.R., Yang W.X., Sun Y. The role of FSH and TGF-β superfamily in follicle atresia. Aging (Albany NY) 2018;10(3):305–21. DOI: 10.18632/aging.101391</mixed-citation><mixed-citation xml:lang="ru">Kazmi S.R.H., Can A.S. Luteinizing hormone deficiency. Treasure Island (FL): StatPearls Publishing, 2024.</mixed-citation></citation-alternatives></ref><ref id="B36"><label>36.</label><citation-alternatives><mixed-citation xml:lang="en">Haldar S., Agrawal H., Saha S. et al. Overview of follicle stimulating hormone and its receptors in reproduction and in stem cells and cancer stem cells. Int J Biol Sci 2022;18(2):675–92. DOI: 10.7150/ijbs.63721</mixed-citation><mixed-citation xml:lang="ru">Hsueh A.J., He J. Gonadotropins and their receptors: coevolution, genetic variants, receptor imaging, and functional antagonists. Biol Reprod 2018;99(1):3–12. DOI: 10.1093/biolre/ioy012</mixed-citation></citation-alternatives></ref><ref id="B37"><label>37.</label><citation-alternatives><mixed-citation xml:lang="en">Sun Y., Qiu F., Hu C. et al. Hemangioma endothelial cells and hemangioma stem cells in infantile hemangioma. Ann Plast Surg 2022;88(2):244–9. DOI: 10.1097/SAP.0000000000002835</mixed-citation><mixed-citation xml:lang="ru">Chu Y.L., Xu Y.R., Yang W.X., Sun Y. The role of FSH and TGF-β superfamily in follicle atresia. Aging (Albany NY) 2018;10(3):305–21. DOI: 10.18632/aging.101391</mixed-citation></citation-alternatives></ref><ref id="B38"><label>38.</label><citation-alternatives><mixed-citation xml:lang="en">Hong Z., Kuang J., Guo Y. et al. Effects of follicle-stimulating hormone on the proliferation and apoptosis of infantile hemangioma stem cells. Biochem Biophys Rep 2023;35:101551. DOI: 10.1016/j.bbrep.2023.101551</mixed-citation><mixed-citation xml:lang="ru">Haldar S., Agrawal H., Saha S. et al. Overview of follicle stimulating hormone and its receptors in reproduction and in stem cells and cancer stem cells. Int J Biol Sci 2022;18(2):675–92. DOI: 10.7150/ijbs.63721</mixed-citation></citation-alternatives></ref><ref id="B39"><label>39.</label><citation-alternatives><mixed-citation xml:lang="en">Ben-Jonathan N., Hugo E. Prolactin (PRL) in adipose tissue: regulation and functions. Adv Exp Med Biol 2015;846:1–35. DOI: 10.1007/978-3-319-12114-7_1</mixed-citation><mixed-citation xml:lang="ru">Sun Y., Qiu F., Hu C. et al. Hemangioma endothelial cells and hemangioma stem cells in infantile hemangioma. Ann Plast Surg 2022;88(2):244–9. DOI: 10.1097/SAP.0000000000002835</mixed-citation></citation-alternatives></ref><ref id="B40"><label>40.</label><citation-alternatives><mixed-citation xml:lang="en">Borba V.V., Zandman-Goddard G., Shoenfeld Y. Prolactin and autoimmunity. Front Immunol 2018;9:73. DOI: 10.3389/fimmu.2018.00073</mixed-citation><mixed-citation xml:lang="ru">Hong Z., Kuang J., Guo Y. et al. Effects of follicle-stimulating hormone on the proliferation and apoptosis of infantile hemangioma stem cells. Biochem Biophys Rep 2023;35:101551. DOI: 10.1016/j.bbrep.2023.101551</mixed-citation></citation-alternatives></ref><ref id="B41"><label>41.</label><citation-alternatives><mixed-citation xml:lang="en">Makotela Y., Triebel J., Clapp K. Time for a new look at the role of prolactin in metabolism. Trends Endocrinol Metab 2020;31(4):276–86. DOI: 10.1016/j.tem.2020.01.004</mixed-citation><mixed-citation xml:lang="ru">Ben-Jonathan N., Hugo E. Prolactin (PRL) in adipose tissue: regulation and functions. Adv Exp Med Biol 2015;846:1–35. DOI: 10.1007/978-3-319-12114-7_1</mixed-citation></citation-alternatives></ref><ref id="B42"><label>42.</label><citation-alternatives><mixed-citation xml:lang="en">Devesa J., Caicedo D. The role of growth hormone on ovarian functioning and ovarian angiogenesis. Front Endocrinol (Lausanne) 2019;10:450. DOI: 10.3389/fendo.2019.00450</mixed-citation><mixed-citation xml:lang="ru">Borba V.V., Zandman-Goddard G., Shoenfeld Y. Prolactin and autoimmunity. Front Immunol 2018;9:73. DOI: 10.3389/fimmu.2018.00073</mixed-citation></citation-alternatives></ref><ref id="B43"><label>43.</label><citation-alternatives><mixed-citation xml:lang="en">Huang Z., Huang L., Waters M.J., Chen C. Insulin and growth hormone balance: Implications for obesity. Trends Endocrinol Metab 2020;31(9):642–54. DOI: 10.1016/j.tem.2020.04.005</mixed-citation><mixed-citation xml:lang="ru">Makotela Y., Triebel J., Clapp K. Time for a new look at the role of prolactin in metabolism. Trends Endocrinol Metab 2020;31(4):276–86. DOI: 10.1016/j.tem.2020.01.004</mixed-citation></citation-alternatives></ref><ref id="B44"><label>44.</label><citation-alternatives><mixed-citation xml:lang="en">Roelfsema F., Yang R.J., Bowers C.Y., Veldhuis J.D. Modulating effects of progesterone on spontaneous nocturnal and ghrelin-induced GH secretion in postmenopausal women. J Clin Endocrinol Metab 2019;104(6):2385–94. DOI: 10.1210/jc.2018-02639</mixed-citation><mixed-citation xml:lang="ru">Devesa J., Caicedo D. The role of growth hormone on ovarian functioning and ovarian angiogenesis. Front Endocrinol (Lausanne) 2019;10:450. DOI: 10.3389/fendo.2019.00450</mixed-citation></citation-alternatives></ref><ref id="B45"><label>45.</label><citation-alternatives><mixed-citation xml:lang="en">Cuny T., Graillon T., Defilles C. et al. Characterization of the ability of a second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells. Pituitary 2021;24(3):351–8. DOI: 10.1007/s11102-020-01113-4</mixed-citation><mixed-citation xml:lang="ru">Huang Z., Huang L., Waters M.J., Chen C. Insulin and growth hormone balance: Implications for obesity. Trends Endocrinol Metab 2020;31(9):642–54. DOI: 10.1016/j.tem.2020.04.005</mixed-citation></citation-alternatives></ref><ref id="B46"><label>46.</label><citation-alternatives><mixed-citation xml:lang="en">Bando H., Yamamoto M., Urai S. et al. Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis. J Immunother Cancer 2024;12(2):e008634. DOI: 10.1136/jitc-2023-00863</mixed-citation><mixed-citation xml:lang="ru">Roelfsema F., Yang R.J., Bowers C.Y., Veldhuis J.D. Modulating effects of progesterone on spontaneous nocturnal and ghrelin-induced GH secretion in postmenopausal women. J Clin Endocrinol Metab 2019;104(6):2385–94. DOI: 10.1210/jc.2018-02639</mixed-citation></citation-alternatives></ref><ref id="B47"><label>47.</label><mixed-citation>Cuny T., Graillon T., Defilles C. et al. Characterization of the ability of a second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells. Pituitary 2021;24(3):351–8. DOI: 10.1007/s11102-020-01113-4</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Bando H., Yamamoto M., Urai S. et al. Fluctuations in plasma adrenocorticotropic hormone concentration may predict the onset of immune checkpoint inhibitor-related hypophysitis. J Immunother Cancer 2024;12(2):e008634. DOI: 10.1136/jitc-2023-00863</mixed-citation></ref></ref-list></back></article>
